Roche Holding AG Virtual EHA 2023 Event: Crovalimab in Hematology and Nephrology Transcript
(Operator Instructions) One last remark, if you would like to follow the presented slides on your end as well, please feel free to go to roche.com/investors to download the presentation.
At this time, it's my pleasure to introduce you to Bruno Eschli, Head of Investor Relations. Bruno, the stage is yours.
Thanks a lot, Henry. And can I have the first slide, please?
So welcome to our third IR call in 2023, this time focusing on crovalimab. The crovalimab development program, especially on PNH, the results presented at EHA and also on our emerging nephrology franchise. And let me quickly make an upfront statement here. I think the nephrology franchise, which today already consists of 4 medicines, we'll have a first major readout to come next year in 2024, with Gazyva and lupus nephritis. And based on the very strong Phase II results, this indication also got a breakthrough therapy designation. So the overall opportunity, which we flagged here for Gazyva in lupus nephritis in SLE in membranous
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |